All In Biotech

BLA 125557 · Amgen

Blincyto

Blinatumomab · Injection

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 3, 2014

Approved uses

9

Original approval plus efficacy supplements

Registered trials

176

30 Phase 3, 59 recruiting

FAERS reports

10,722

8,619 serious, 1,935 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) ] . Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended [see Dosage and Administration (2.4) , Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME See full prescribing information for complete boxed warning....

What it is approved for

From the label in effect Apr 14, 2026.

BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 ) 1.1 MRD-positive B-cell Precursor ALL BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older. 1.2 Relapsed or Refractory B-cell Precursor ALL BLINCYTO is indicated for the treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older. 1.3 B-cell Precursor ALL in the Consolidation Phase BLINCYTO is indicated for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older.

Mechanism: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. Blinatumomab mediates the formation of a synapse between the T-cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, which result in redirected lysis of CD19+ cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 14, 2024 Supplement 28 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jun 20, 2023 Supplement 23 · Efficacy OrphanLabelLetter
  • Jun 20, 2023 Supplement 26 · Efficacy · priority review OrphanLabelLetter
  • Mar 11, 2021 Supplement 18 · Efficacy · priority review Orphan
  • Mar 11, 2021 Supplement 20 · Efficacy · priority review LabelLetter
  • Mar 29, 2018 Supplement 13 · Efficacy · priority review OrphanLabelLetterReview
  • Jul 11, 2017 Supplement 8 · Efficacy · priority review OrphanLabelLetter
  • Aug 30, 2016 Supplement 5 · Efficacy · priority review OrphanLetterLabelReview
  • Dec 3, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelReviewPediatric Medical Review
1 products under this application
  • BLINCYTO · BLINATUMOMAB 35MCG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Blinatumomab" as an intervention, any sponsor and status, largest first.

All 176 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia1,187
  • cytokine release syndrome1,150
  • acute lymphocytic leukaemia recurrent1,121
  • off label use793
  • death674
  • neurotoxicity584
  • drug ineffective448
  • headache379
  • neutropenia333
  • febrile neutropenia313
  • therapy non-responder291
  • tremor287

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20148
2015446
2016712
2017808
2018803
2019865
2020789
20211,013
2022959
20231,100
20241,297
20251,065
2026857

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Blincyto (Blinatumomab)

2024 spending

$1.7M

Beneficiaries

n/a

48 claims

Per beneficiary

n/a

$5,125.93 per unit

View as table
YearSpending
2020$1,119,120
2021$2,005,937
2022$1,327,683
2023$1,523,068
2024$1,704,009

Part B: Blincyto (Blinatumomab) · HCPCS J9039

2024 spending

$86.2M

Beneficiaries

357

3,233 claims

Per beneficiary

$241,533

2024 ASP limit $148.76 per unit

View as table
YearSpending
2020$24,174,501
2021$27,936,547
2022$34,078,269
2023$73,167,103
2024$86,227,273

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 111 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.